Investor Portal

From lab to life

Together

Approach

Team

Portfolio

Backing bold science. Building enduring companies.

At Bioqube Ventures, we help science succeed by turning discoveries into transformative medicines.

Bioqube Ventures is a global life sciences investment firm with offices in Belgium and the United States. We invest in companies developing first- or best-in-class therapeutics to address major unmet medical needs. Being stage agnostics, we build balanced portfolios supporting companies from inception through early clinical milestones.

Backing bold science. Building enduring companies.

Latest news

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

2025-10-21

$CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025$

CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025

2025-10-20

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

2025-10-17

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

2025-10-13

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

2025-09-30

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025

2025-09-23

Bioqube Ventures Appoints Tom Heyman as Executive Partner

2025-09-18

CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development

CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development

2025-09-15

Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy

Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy

2025-08-27

SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline

SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline

2025-07-09

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

2025-07-09

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

2025-06-10

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

2025-06-04

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

2025-06-04

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

2025-05-30

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

2025-04-14

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting

2025-04-14

SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy

2025-04-01

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

2025-01-28

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

2025-01-22

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

2025-01-13

Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies

2025-01-09

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

2025-01-08

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

2024-10-30

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial

2024-10-15

Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US

Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US

2024-10-09

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

2024-10-09

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2024-09-16

Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.

Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.

2024-08-15

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

2024-06-20

Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

2024-05-15

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

2024-05-10

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

2024-05-09

SynOx Therapeutics secures up to $35m debt financing with Hercules Capital

SynOx Therapeutics secures up to $35m debt financing with Hercules Capital

2024-04-30

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

2024-04-30

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

2024-04-24

Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting

Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting

2024-04-04

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

2024-03-26

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

2024-03-20

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

2024-01-31

Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing

Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing

2023-12-12

Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023

Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023

2023-10-23

Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson

Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson

2023-10-16

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

2023-10-11

Anavo Therapeutics strengthens management team

Anavo Therapeutics strengthens management team

2023-09-21

Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer

Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer

2023-07-24

Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

2023-06-05

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic

2023-05-02

Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

2023-04-18

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

2023-03-14

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer

2023-03-06

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

2022-10-20

Tridek-one closes a €16 million financing round to develop first-in-class immune checkpoint agonists

Tridek-one closes a €16 million financing round to develop first-in-class immune checkpoint agonists

2022-09-25

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

2022-05-26

Lonza and Bioqube Ventures Sign a Framework Agreement for the Future Development and Manufacture of Biologics and Small Molecules for Bioqube’s Portfolio Companies

2021-11-30

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

2021-11-04

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

2021-11-02

Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster

Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster

2021-08-16

Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers

Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers

2021-08-16

Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

2021-06-24

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

2021-04-22

Primmune Therapeutics Strengthens Leadership Team with Key Appointments

Primmune Therapeutics Strengthens Leadership Team with Key Appointments

2021-02-05

Primmune Therapeutics Announces Close of Series A Financing

Primmune Therapeutics Announces Close of Series A Financing

2021-01-12

Bioqube Ventures welcomes two seasoned professionals

2020-09-24

Bioqube Ventures launches Bioqube Factory Fund I

2020-06-10